Genetically Engineered Biomimetic Nanovesicles Co-Deliveing a Checkpoint Inhibitor and Doxorubicin for Enhanced Cancer Chemo-Immunotherapy.

Yunying Xing, Xinyi Liu, Zhenkun Wang, Yingze Wang, Jing Zhang, Wenxiang Zhu

Abstract read

In one paragraph

Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yunying XingCollege of Food Science and Biology, Hebei University of Science and Technology, Shijiazhuang 050000, China.

Xinyi LiuState Key Laboratory of Medical Proteomics, National Center for Protein Sciences at Beijing, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, Beijing 100000, China.ORCID 0000-0002-1580-1594

Zhenkun WangCollege of Food Science and Biology, Hebei University of Science and Technology, Shijiazhuang 050000, China.

Yingze WangCollege of Food Science and Biology, Hebei University of Science and Technology, Shijiazhuang 050000, China.ORCID 0000-0003-2775-5166

Jing ZhangCollege of Food Science and Biology, Hebei University of Science and Technology, Shijiazhuang 050000, China.

Wenxiang ZhuAier Glaucoma Institute, Hunan Engineering Research Center for Glaucoma with Artificial Intelligence in Diagnosis and Application of New Materials, Changsha Glaucoma Diagnosis and Treatment Technology Innovation Center, Changsha Aier Eye Hospital, Changsha 410015, China.ORCID 0009-0001-2392-6661

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

breast cancerchemotherapycombination therapydoxorubicingenetic engineering of cell membranesimmune checkpoint blockade

Identifiers

PMID41754902

DOI10.3390/pharmaceutics18020159

PMCPMC12944562

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.